In a recent update, InMed Pharmaceuticals president and CEO, Eric A. Adams, lauded the company’s progress and achievements so far, particularly with its product diversification and strategic acquisitions Adams noted the company’s commitment to launching more products and executing more programs to continue growing its product portfolio InMed also announced the appointment of Gerald (“Jerry”) … Continue reading “InMed Pharmaceuticals Inc. (NASDAQ: INM) Updates Recent Product Diversification Efforts and Strategic Acquisitions Developments; Announces VP Of Sales & Marketing Appointment”
InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that its president and CEO Eric A. Adams will be presenting at the 34th Annual Roth Conference being held March 13-15, 2022. Adams will host a fireside chat with Scoth Henry, managing director and head of pharmaceuticals … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at 34th Annual Roth Conference”
InMed Pharmaceuticals (NASDAQ: INM) is uniquely positioned to leverage the growing worldwide awareness of the potential of cannabinoids and the rising demand for rare cannabinoids. The company has begun this year on a high, following the 2021 acquisition of BayMedica and the launch of cannabicitran (“CBT”) sales. “With the launch of business-to-business sales of CBT … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expanding Portfolio, Presence in Growing Rare Cannabinoid Market”
Over 140 rare cannabinoids exist in the cannabis plant – some with the potential to have more therapeutic benefits than those cannabinoids found prominently in the plant InMed and subsidiary BayMedica plan to release several rare cannabinoid products in the first half of 2022 Combination of complementary InMed and BayMedica business models key to increasing … Continue reading “InMed Pharmaceuticals Inc. (NASDAQ: INM) and BayMedica Rare Cannabinoids to Enter Market Q1 2022; Leveraging on Fast-Growing Global Health and Wellness Market”
InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, was featured in a report published by Edison Group, a leading research and investor relations consultancy. According to the piece, InMed achieved Q222 financial results that reflect its evolution from a pure-play biotech firm to one with commercial sales … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Evolution to Commercial Sales to Health and Wellness Market Featured in Research Report”
InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has appointed Gerard (Jerry) P. Griffin III as vice president of sales and marketing at BayMedica, a wholly owned subsidiary of InMed. In his new role, Griffin will manage the commercialization of BayMedica’s health and wellness business including existing … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names BayMedica VP of Sales, Releases Q2 2022 Report”
InMed Pharmaceuticals (NASDAQ: INM) understands the immense potential of rare cannabinoids and sees them as having applications as wide as cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”), variants of cannabinoids that make up most of the content in cannabis plants. Studies suggest that rare cannabinoids could offer more potent medical benefits than CBD and without the psychoactive … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) in Unique Position to Offer Full Slate of Rare Cannabinoid Manufacturing Technologies”
InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has announced that it will report its second-quarter financial results next week on Feb. 15, 2022; the results will cover the period ending Dec. 31, 2021. The company has scheduled a conference call and webcast to discuss the report; the … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Release Q2 Financial Report, Business Update”
Cannabicitran is the first of four new rare cannabinoids InMed is planning to launch in the first half of the year to meet growing inbound demand The launch demonstrates InMed’s ability to produce rare cannabinoids at scale, something only very few companies have achieved BayMedica acquisition, other key achievements in 2021, are positioning the company … Continue reading “InMed Pharmaceuticals Inc. (NASDAQ: INM) Strengthens Leading Role in Rare Cannabinoid Market Following New Product Launch, Key Acquisition”
InMed Pharmaceuticals (NASDAQ: INM) is a trailblazer, a pioneer defining the value of rare cannabinoids in the pharmaceutical sector and just how integral they are in pushing the industry forward. The global cannabis market is experiencing tremendous growth, particularly considering there are over 100 known cannabinoids, including rare ones that are quickly taking over and … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Blazing Trail in Defining Value of Rare Cannabinoids in Pharmaceutical Space”
